FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
The FDA approved Lipfendra, the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with high cholesterol.
Reported by 1 outlet — FDA. See all sources ↓
The US FDA approved a new medicine called Lipfendra. It helps lower bad cholesterol in adults with high cholesterol. This medicine is taken once a day as a tablet.
Why it matters
This new medicine gives people with high cholesterol another option to lower their bad cholesterol levels.
- What is PCSK9?
- PCSK9 is a protein that helps control cholesterol levels in the body.
- What is LDL cholesterol?
- LDL cholesterol is called 'bad' cholesterol because it can cause heart problems.
- What is Lipfendra?
- Lipfendra is a new medicine that lowers LDL cholesterol levels in adults with high cholesterol.
How outlets are framing the same story
These are the main editorial angles found across reporting. Use them to quickly compare what different outlets emphasize, omit, or question.
All outlets report the FDA approval of Lipfendra in a similar way, focusing on the new treatment option for adults with high cholesterol.
- Coverage cardFraming signal1AngleScouting report
FDA approval of new cholesterol-lowering medicine
Sources1TypeAngleFDAofficial announcement